Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2026 | Zedoresertib and lunresertib shows activity in genomically altered tumors

Timothy Yap • 10 Apr 2026
AACR 2026
General Lunresertib Zedoresertib

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, explores data from a Phase I trial (NCT04855656) of zedoresertib with lunresertib in advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A alterations. The first-in-class synthetic lethal combination of WEE1 and PKMYT1 inhibitors demonstrated a manageable safety profile and encouraging early antitumor activity. Pharmacokinetic and pharmacodynamic analyses confirmed target engagement, while circulating tumor DNA responses support continued dose optimization and further clinical development. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Timothy Yap

PLN-101095 shows promise in immune checkpoint inhibitor-resistant tumors
6:18
PLN-101095 shows promise in immune checkpoint inhibitor-resistant tumors
Timothy Yap • 10 Apr 2026
Phase I/II trial of BNT142, an mRNA encoded bsAb, in CLDN6+ solid tumors
2:59
Phase I/II trial of BNT142, an mRNA encoded bsAb, in CLDN6+ solid tumors
Timothy Yap • 2 Jun 2025
KEYLYNK-007: olaparib and pembrolizumab in HRRm cancers
3:19
KEYLYNK-007: olaparib and pembrolizumab in HRRm cancers
Timothy Yap • 6 May 2025
Assessing RO7589831, a WRN inhibitor, in MSI/dMMR solid tumors
6:55
Assessing RO7589831, a WRN inhibitor, in MSI/dMMR solid tumors
Timothy Yap • 6 May 2025

Related Videos

YOCAS, mood disturbance and insomnia in cancer survivors
1:19
YOCAS, mood disturbance and insomnia in cancer survivors
Karen Mustian • 30 May 2026
Does YOCAS produce long-term benefits in mood disturbances and insomnia in cancer survivors?
0:45
Does YOCAS produce long-term benefits in mood disturbances and insomnia in cancer survivors?
Karen Mustian • 30 May 2026
Implementation of YOCAS into a clinical setting
2:32
Implementation of YOCAS into a clinical setting
Karen Mustian • 30 May 2026
Can steroid use as antiemetic prophylaxis be avoided in pediatric and adolescent patients?
1:00
Can steroid use as antiemetic prophylaxis be avoided in pediatric and adolescent patients?
Venkatraman Radhakrishnan • 30 May 2026
The content of VJOncology is intended for healthcare professionals